Canada’s public drug plans should not pay for a new medication that slows cognitive decline in patients with Alzheimer’s disease because it’s not clear the expensive therapy provides clinically ...
A New Brunswick neurologist, who was one of four doctors who alerted heath officials about neurological symptoms plaguing hundreds of patients, is renewing his call for an independent scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results